GleamWall
中文EN

GCTK Glucotrack, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1506983 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY40.4%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-620.6%
ROA-272.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets216.5%
Debt / equity—
Current ratio0.46x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$2.02M$2.13M$1.63M$3.17M$3.15M$1.87M$1.70M$2.06M
SG&A expense$1.38M$2.07M$2.29M$1.02M$1.65M$1.63M$2.06M$1.06M
Operating income-$3.40M-$4.20M-$3.49M-$4.31M-$4.80M-$3.50M-$3.85M-$3.25M
Interest expense——————$39,000$5,000
Net income-$3.81M-$4.33M-$3.63M-$4.17M-$4.76M-$6.83M-$10.09M-$5.09M
EBITDA-$3.38M-$4.18M-$3.47M-$4.30M-$4.79M-$3.49M-$3.84M-$3.24M
EPS (basic)0.762.65—4.649.6240.14—1,092.00
EPS (diluted)0.762.65—4.649.6240.14—1,092.00
Weighted avg. shares (diluted)5.01M1.64M—899,410494,504169,345—4,663
Balance sheet
Cash & equivalents$1.12M$3.93M$7.38M$7.87M$9.55M$9.10M$5.62M$346,000
Current assets$1.38M$4.21M$7.67M$8.11M$10.08M$9.46M$5.77M$642,000
PP&E, net$95,000$116,000$138,000$144,000$87,000$94,000$95,000$109,000
Total assets$1.50M$4.36M$7.84M$8.29M$10.21M$9.61M$5.93M$826,000
Current liabilities$2.99M$4.97M$4.77M$5.30M$3.08M$1.95M$1.27M$4.61M
Total liabilities$3.24M$5.21M$5.01M$5.54M$3.33M$2.35M$18.93M$4.85M
Shareholders' equity-$1.74M-$851,000$2.83M$2.75M$6.88M$7.26M-$13.00M-$4.02M
Shares outstanding6.26M2.52M910,688899,410899,41025.59M13,4095.77M
Cash flow statement
Operating cash flow-$3.62M-$4.05M-$3.94M-$4.62M-$3.74M-$2.94M-$3.50M-$4.14M
Capital expenditure——$20,000$67,000$0$9,000$0$33,000
Free cash flow——-$3.96M-$4.69M-$3.74M-$2.95M-$3.50M-$4.17M
Investing cash flow——-$20,000-$67,000$0-$9,000$0-$33,000
Financing cash flow$803,000$591,000$3.49M$2.99M$4.16M$6.39M$8.78M$4.38M
Depreciation & amortization$21,000$22,000$14,000$9,000$11,000$8,000$14,000$10,000
Stock-based compensation$59,000$61,000$90,000$41,000$40,000$40,000-$66,000$11,000

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.